This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SAN DIEGO, Feb. 8, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced that Chief Executive Officer Roger L. Hawley, along with Executive Vice President and Chief Financial Officer Ann Rhoads, will participate in the Leerink Swann Hot Topics in Therapeutics Roundtable Conference to be held February 16-17, 2011 at The Roosevelt Hotel in New York City.
During the Conference, Mr. Hawley will also represent Zogenix on a panel of executives from leading neurology/pain companies. Mr. Hawley and Ms. Rhoads will be available to respond to questions and to participate in one-on-one meetings with investors attending the conference.
Leerink Swann Hot Topics in Therapeutics Roundtable Conference
Thursday, February 17, 2011
10:25am ET (presentation); 11:00am ET (Neuro/Pain panel)
The Roosevelt Hotel, New York, NY (Terrace Ballroom, lobby level)
The presentation will be web cast live and archived for 90 days on Zogenix' Investor Relations website at ir.zogenix.com. The panel discussion will not be web cast.
Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL
® DosePro™ (
sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead product candidate, ZX002, is a novel, oral, single-entity controlled-release formulation of
hydrocodone currently in Phase 3 clinical trials for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy.
For additional information, please visit
The Ruth Group
The Ruth Group